指南与共识产科母胎医学

ACOG 委员会意见第751号:人类免疫缺陷病毒感染女性的分娩与接生管理

ACOG Committee Opinion No. 751: Labor and Delivery Management of Women With Human Immunodeficiency Virus Infection.
指南 / 共识 · Obstet Gynecol · 2018-01-01

本委员会意见更新了感染人类免疫缺陷病毒(HIV)孕妇的孕期与分娩管理建议,以预防母婴传播。持续联合抗逆转录病毒治疗且分娩时或临近分娩时病毒载量≤1,000拷贝/mL的孕妇,阴道分娩是合适的;高病毒载量者可在临产和破膜前行计划剖宫产以降低传播风险。应与每位HIV感染孕妇尽早讨论计划剖宫产的选择,尊重其在讨论母婴风险后的分娩方式决定。

要点

  • 联合抗逆转录病毒治疗且维持病毒载量≤1,000拷贝/mL时,母婴传播风险可降至1-2%或更低,与分娩方式及破膜时间无关。
  • 病毒载量≤1,000拷贝/mL的HIV感染孕妇,阴道分娩是合适的。
  • 高病毒载量者可在临产和破膜前行计划剖宫产,并配合围产期母体抗逆转录病毒治疗,以降低母婴传播风险。

核心结论

  • 持续联合抗逆转录病毒治疗且维持母体病毒载量≤1,000拷贝/mL时,母婴传播风险可达1-2%或更低,与分娩方式或分娩前破膜时间无关。
  • 病毒载量≤1,000拷贝/mL的HIV感染孕妇,阴道分娩是合适的。
  • 高病毒载量HIV感染孕妇,在临产和破膜前行计划剖宫产并配合围产期母体抗逆转录病毒治疗,可降低母婴传播风险。

研究设计与样本

  • 美国妇产科医师学会(ACOG)发布的委员会意见,对感染HIV孕妇的孕期与分娩管理提供更新指导。

主要发现

  • 持续研究提示,相当数量围产期HIV传播病例源于分娩过程中胎儿暴露于病毒,但确切机制尚不清楚。
  • 已确立并持续进行的研究显示,联合抗逆转录病毒治疗可使维持母体病毒载量≤1,000拷贝/mL的HIV感染孕妇的母婴传播风险达1-2%或更低,与分娩方式或分娩前破膜时间无关。

关键数值与推荐

  • 病毒载量≤1,000拷贝/mL(分娩时或临近分娩时)的HIV感染孕妇,阴道分娩是合适的。
  • 高病毒载量者可在临产和破膜前行计划剖宫产,并配合围产期母体抗逆转录病毒治疗,以降低母婴传播风险。
  • 应在孕期尽早与每位HIV感染孕妇讨论计划剖宫产的选择及其在病毒抑制不理想情况下的优势。
  • 在讨论母婴风险后,应尊重患者关于分娩方式的选择。

临床怎么用

  • 对持续联合抗逆转录病毒治疗且病毒载量≤1,000拷贝/mL的HIV感染孕妇,阴道分娩是合适的。
  • 对高病毒载量者,可考虑在临产和破膜前行计划剖宫产,并配合围产期母体抗逆转录病毒治疗。
  • 应在孕期尽早与每位HIV感染孕妇讨论计划剖宫产的选择及其在病毒抑制不理想情况下的优势。
  • 在讨论母婴风险后,应尊重患者关于分娩方式的选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This Committee Opinion is being revised to provide updated guidance on the management of pregnant women during pregnancy and delivery to prevent mother-to-child transmission of the human immunodeficiency virus (HIV). Prevention of transmission of HIV from the woman to her fetus or newborn is a major goal in the care of pregnant women infected with HIV. Continuing research into mother-to-child transmission of HIV has suggested that a substantial number of cases of perinatal HIV transmission occur as the result of fetal exposure to the virus during labor and delivery. The precise mechanisms are not known. Established and ongoing research has shown that treatment of HIV-infected pregnant women with combined antiretroviral therapy can achieve a 1-2% or lower risk of mother-to-child transmission if maternal viral loads of 1,000 copies/mL or less can be sustained, independent of the route of delivery or duration of ruptured membranes before delivery. Vaginal delivery is appropriate for HIV-infected pregnant women who have been maintained on combined antiretroviral therapy and who have viral loads of 1,000 copies/mL or less at or near delivery. The risk of mother-to-child transmission in HIV-infected women with high viral loads can be reduced by performing cesarean deliveries before the onset of labor and before rupture of membranes (termed scheduled cesarean delivery in this document), in conjunction with the use of peripartum maternal antiretroviral therapy. Discussion of the option of scheduled cesarean delivery and its advantages in the situation of suboptimal viral suppression should begin as early as possible in pregnancy with every pregnant woman with HIV infection to give her an adequate opportunity to ask questions and consider her decision-making concerning the delivery plan. The patient's decision regarding her route of delivery should be respected after maternal and neonatal risks have been discussed.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. ACOG Committee Opinion No. 751: Labor and Delivery Management of Women With Human Immunodeficiency Virus Infection. Obstet Gynecol. 2018. PMID: 30134427. doi:10.1097/AOG.0000000000002820

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。